Literature DB >> 1314165

p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer.

T Unger1, M M Nau, S Segal, J D Minna.   

Abstract

Gal4-p53 fusion constructs demonstrate that wild type p53 is a potent transactivator in human lung cancer cells with the transactivation domain for p53 residing in amino acids 1-42. Strikingly, a variety of lung cancer derived p53 mutations occurring outside this domain disrupt this activity. Temperature sensitive conformational shifts of p53 mutant proteins to the wild type form exist and, with a temperature downshift, several mutants become transcriptionally active. Wild type p53 protein is known to form oligomers with mutant p53 and cotransfection of wild type and mutant genes shows that p53 acts in a transdominant manner that is independent of the DNA binding specificity. Transcription is either increased or decreased depending on whether the wild type is more or less abundant than the mutant form. Finally, lung cancers differ in their ability to support the transactivation related functions, providing evidence of other abnormalities of the p53 system in human cancer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1314165      PMCID: PMC556587          DOI: 10.1002/j.1460-2075.1992.tb05183.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  35 in total

1.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription.

Authors:  G J Kato; J Barrett; M Villa-Garcia; C V Dang
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  The MCK enhancer contains a p53 responsive element.

Authors:  H Weintraub; S Hauschka; S J Tapscott
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

3.  Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product.

Authors:  W G Kaelin; D C Pallas; J A DeCaprio; F J Kaye; D M Livingston
Journal:  Cell       Date:  1991-02-08       Impact factor: 41.582

4.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

Review 5.  Structural aspects of the p53 protein in relation to gene evolution.

Authors:  T Soussi; C Caron de Fromentel; P May
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

6.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

7.  Temperature-dependent switching between "wild-type" and "mutant" forms of p53-Val135.

Authors:  J Milner; E A Medcalf
Journal:  J Mol Biol       Date:  1990-12-05       Impact factor: 5.469

Review 8.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

9.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group.

Authors:  I Chiba; T Takahashi; M M Nau; D D'Amico; D T Curiel; T Mitsudomi; D L Buchhagen; D Carbone; S Piantadosi; H Koga
Journal:  Oncogene       Date:  1990-10       Impact factor: 9.867

10.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.

Authors:  R Zakut-Houri; B Bienz-Tadmor; D Givol; M Oren
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

View more
  85 in total

1.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

4.  Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.

Authors:  T Unger; T Juven-Gershon; E Moallem; M Berger; R Vogt Sionov; G Lozano; M Oren; Y Haupt
Journal:  EMBO J       Date:  1999-04-01       Impact factor: 11.598

5.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

6.  The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.

Authors:  Jennifer M Smith; Lawton J Stubbert; Jeffrey D Hamill; Bruce C McKay
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

7.  Molecular dynamics simulations of p53 DNA-binding domain.

Authors:  Qiang Lu; Yu-Hong Tan; Ray Luo
Journal:  J Phys Chem B       Date:  2007-09-08       Impact factor: 2.991

8.  Distinct residues of human p53 implicated in binding to DNA, simian virus 40 large T antigen, 53BP1, and 53BP2.

Authors:  S K Thukral; G C Blain; K K Chang; S Fields
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors.

Authors:  B Roy; J Beamon; E Balint; D Reisman
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  p53: a molecular marker for the detection of cancer.

Authors:  Mark T Boyd; Nikolina Vlatkovic
Journal:  Expert Opin Med Diagn       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.